Analyzing Luminex (NASDAQ:LMNX) & Nuvectra (NASDAQ:NVTR)

Luminex (NASDAQ:LMNX) and Nuvectra (NASDAQ:NVTR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Risk & Volatility

Luminex has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Nuvectra has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Earnings and Valuation

This table compares Luminex and Nuvectra’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Luminex $315.82 million 2.82 $18.51 million $0.48 41.27
Nuvectra $48.83 million 0.74 -$48.13 million ($3.19) -0.64

Luminex has higher revenue and earnings than Nuvectra. Nuvectra is trading at a lower price-to-earnings ratio than Luminex, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

84.7% of Luminex shares are owned by institutional investors. Comparatively, 80.4% of Nuvectra shares are owned by institutional investors. 8.7% of Luminex shares are owned by company insiders. Comparatively, 2.9% of Nuvectra shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dividends

Luminex pays an annual dividend of $0.24 per share and has a dividend yield of 1.2%. Nuvectra does not pay a dividend. Luminex pays out 50.0% of its earnings in the form of a dividend.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Luminex and Nuvectra, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Luminex 0 3 0 0 2.00
Nuvectra 0 0 3 0 3.00

Luminex presently has a consensus target price of $30.00, suggesting a potential upside of 51.44%. Nuvectra has a consensus target price of $19.00, suggesting a potential upside of 835.96%. Given Nuvectra’s stronger consensus rating and higher probable upside, analysts plainly believe Nuvectra is more favorable than Luminex.

Profitability

This table compares Luminex and Nuvectra’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Luminex 2.55% 1.62% 1.44%
Nuvectra -98.77% -62.18% -35.90%

Summary

Luminex beats Nuvectra on 12 of the 16 factors compared between the two stocks.

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

About Nuvectra

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit